000			04557nam a22003735i 4500
001			85626
003			ES-MaUEC
005			20230207040519.0
007			cr nn 008mamaa
008			160530s2016 gw | s |||| 0|eng d
020			_a9783319298276
040			_aES-MaUEC
050		4	_aRC271.I45 _bN684 2016
082	0	4	_a616.079
245	1	0	_aNovel Immunotherapeutic Approaches to the Treatment of Cancer : _bDrug Development and Clinical Application _cedited by Paul D Rennert
260			_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XI, 276 páginas) _b25 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aIntroduction -- Enhancing the efficacy of checkpoint blockade through combination therapies -- Novel Immunomodulatory Targets in the Immunoglobulin-Superfamily -- Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27 and CD137 -- NK Cell Responses in Immunotherapy -- Reversing T cell dysfunction for tumor immunotherapy -- Immunomodulation within a single tumor site to induce systemic anti-tumor immunity -- Novel Targets and Their Assessment for Cancer Treatment -- The New Frontier of Antibody Drug Conjugates -- Cellular Therapies -- Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer.
520	3		_aCancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers. .
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, asignarmaterias , EBSPRINGER
650		7	_aMedicina _0comprobar BNE19900959047 _2embne _9405021
650		7	_aCáncer _xInvestigación _0comprobar BNE19901364217 _2embne _9182523
700	1		_aRennert, Paul D. _eeditor literario _998746 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-29827-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319298276
907			_a.b12949048 _b10-10-17 _c21-11-16
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC271.I45 N684 2016 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11592357 _z06-04-17
999			_c85626 _d85626 _x1